We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 72.4%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STML
76
DELISTED
Stemline Therapeutics, Inc.
STML
$3.92M 0.03%
333,497
– –
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.84M 0.03%
250,000
– –
CRIS icon
78
Curis
CRIS
$9.67M
$3.57M 0.03%
+539
New +$3.24M
ENTA icon
79
Enanta Pharmaceuticals
ENTA
$363M
$3.39M 0.03%
75,357
– –
ITCI
80
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.33M 0.03%
104,166
– –
IONS icon
81
Ionis Pharmaceuticals
IONS
$9.03B
$3.29M 0.03%
57,140
– –
TARA icon
82
Protara Therapeutics
TARA
$213M
$3.16M 0.03%
4,419
+96
+2% +$59.4K
IMDZ
83
DELISTED
Immune Design Corp.
IMDZ
$3.08M 0.03%
+148,937
New +$3.52M
BLPH
84
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.78M 0.02%
23,333
– –
VTAE
85
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.7M 0.02%
187,597
– –
WINT
86
DELISTED
Windtree Therapeutics Inc
WINT
$2.43M 0.02%
254,975
– –
MRNS
87
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.32M 0.02%
50,000
– –
SVRA icon
88
Savara
SVRA
$1.07B
$2.31M 0.02%
67,249
– –
TCRT icon
89
Alaunos Therapeutics
TCRT
$4.71M
$2.27M 0.02%
1,262
– –
ABUS icon
90
Arbutus Biopharma
ABUS
$845M
$2.14M 0.02%
180,582
– –
AUPH icon
91
Aurinia Pharmaceuticals
AUPH
$1.92B
$2.13M 0.02%
711,499
– –
IRWD icon
92
Ironwood Pharmaceuticals
IRWD
$591M
$2.04M 0.02%
201,981
– –
ISEE
93
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.86M 0.02%
35,649
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$1.83M 0.02%
+100,000
New +$1.72M
PTN
95
Palatin Technologies
PTN
$14.1M
$1.82M 0.02%
1,640
– –
CLLS
96
Cellectis
CLLS
$287M
$1.8M 0.02%
50,000
– –
LOXO
97
DELISTED
Loxo Oncology, Inc
LOXO
$1.8M 0.02%
100,000
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$13.9M
$1.78M 0.02%
+3
New +$1.75M
ASND icon
99
Ascendis Pharma A/S
ASND
$16.5B
$1.77M 0.02%
100,000
– –
DERM
100
DELISTED
Dermira, Inc.
DERM
$1.75M 0.02%
100,000
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Baker Bros. Advisors held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 40% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Baker Bros. Advisors's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Baker Bros. Advisors's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Baker Bros. Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Baker Bros. Advisors opened 10 new positions and closed 12 in Q2 2015.
  • Baker Bros. Advisors's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.